Table 2.
Patients with isolated relapse in CNS group characteristics at the time of the first diagnosis
| Pts | Age at Dx (y, m) | Gender | Stage at Dx | Primary site Metastases at diagnosis |
MYCN amplification/ Type of pathology |
Skull bones involvement at Dx | First line therapy |
|---|---|---|---|---|---|---|---|
| 1 | 2y 2 m | F | 4 |
Adrenal gland Bones, BM, LN |
Yes UH |
Yes |
HR-NBL SIOPEN No anti-GD2 |
| 2 | 2y 2 m | M | 4 |
Retroperitoneal space Bones, BM, LN |
Yes UH |
Yes – intracranial penetration |
HR-NBL SIOPEN No anti-GD2 |
| 3 | 5 m | F | 4 |
Adrenal gland, Bones, BM, liver, kidneys, lungs, chest wall |
Yes UH |
No |
HR-NBL SIOPEN No anti-GD2 |
| 4 | 3 m | F | 4 |
Adrenal gland Bones, BM, LN, lungs, liver, kidneys |
Yes UH |
No |
HR-NBL SIOPEN With anti-GD2 |
| 5 | 2y 6 m | F | 4 |
Adrenal gland Bones, BM |
Not evaluated UH |
Yes | Conventional chemotherapy |
| 6 | 3y 7 m | F | 4 |
Mediastinum Bones, BM, LN, CSN, pleura |
No UH |
Yes – CNS infiltration | HR-NBL SIOPEN with anti-GD2 |
| 7 | 2y 7 m | M | 4 |
Adrenal gland Bones, BM, LN |
No UH |
Yes | Conventional chemotherapy |
| 8 | 10 m | M | 4 |
Retroperitoneal space BM |
Yes UH |
No |
HR-NBL SIOPEN No anti-GD2 |
| 9 | 11 m | M | 4 |
Adrenal gland Bones, BM, LN |
Yes UH |
Yes – infiltration of skull base |
HR-NBL SIOPEN With anti-GD2 |
| 10 | 2y 4 m | F | 4 |
Retroperitoneal space Bones, BM |
No FH |
Yes |
HR-NBL SIOPEN No anti-GD2 |
| 11 | 1y 8 m | M | 4 |
Adrenal gland LN, mediastinum, bones, BM |
Yes UH |
Yes |
HR-NBL SIOPEN With anti-GD2 |
| 12 | 1y 11 m | M | 4 |
Adrenal gland LN, bones, BM |
Yes UH |
Yes – penetrating to CNS |
HR-NBL SIOPEN With anti-GD2 |
| 13 | 6y 1m2 | M | 4 |
Retroperitoneal space Bones, BM |
No UH |
No |
HR-NBL SIOPEN With anti-GD2 |
Dx diagnosis, y year, m month, M male, F female, UH unfavourable histopathology, FH favourable histopathology, BM bone marrow, LN lymph nodes